Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8.

PMID:
29943159
2.

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M.

Hematol Oncol. 2018 Jun 8. doi: 10.1002/hon.2521. [Epub ahead of print]

PMID:
29882363
3.

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Erratum in: Ann Hematol. 2018 Jun 26;:.

PMID:
29756171
4.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P.

Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002/hon.2383. Epub 2017 Feb 20.

5.

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.

Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30.

PMID:
26420061
6.

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.

Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA.

Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20. No abstract available.

7.

Significance of the detection of paroxysmal nocturnal hemoglobinuria clones in patients with multiple myeloma undergoing autologous stem cell transplantation.

Chatziantoniou V, Alexia S, Konstantopoulos K, Repousis P, Megalakaki A, Kotsopoulou M, Kylidou P, Vassilakopoulos T, Angelopoulou MK.

Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):150-9. doi: 10.1016/j.hemonc.2015.06.008. Epub 2015 Jul 9.

8.

Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek Myeloma Study Group.

Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18.

PMID:
24637336
9.

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.

Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, Repousis P, Terpos E, Dimopoulos MA; Greek Myeloma Study Group.

Eur J Haematol. 2014 Apr;92(4):308-12. doi: 10.1111/ejh.12255. Epub 2014 Jan 26.

PMID:
24460646
10.

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E.

Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483.

PMID:
24356630
11.

Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse.

Papanikolaou X, Repousis P, Tzenou T, Maltezas D, Kotsopoulou M, Megalakaki K, Angelopoulou M, Dimitrakoloulou E, Koulieris E, Bartzis V, Pangalis G, Panayotidis P, Kyrtsonis MC.

Leuk Lymphoma. 2013 Jul;54(7):1459-64. doi: 10.3109/10428194.2012.746683. Epub 2012 Dec 14.

PMID:
23151071
12.

Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.

Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, Panayiotidis P, Delimpasi S, Michalis E, Anargyrou K, Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, Kyrtsonis MC.

Hematol Oncol. 2013 Jun;31(2):96-102. doi: 10.1002/hon.2026. Epub 2012 Sep 7. Erratum in: Hematol Oncol. 2013 Spe;31(3):168.

PMID:
22961993
13.

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K; Greek Myeloma Study Group.

Eur J Haematol. 2012 Jul;89(1):10-5. doi: 10.1111/j.1600-0609.2012.01784.x.

PMID:
22469521
14.

Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation.

Kaloyannidis P, Voutiadou G, Baltadakis I, Tsirigotis P, Spyridonidis A, Repousis P, Balta A, Tsimberis S, Karakasis D, Sakellari I, Dervenoulas I, Harhalakis N, Anagnostopoulos A.

Biol Blood Marrow Transplant. 2012 Mar;18(3):451-7. doi: 10.1016/j.bbmt.2011.07.020. Epub 2011 Jul 29.

15.

Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.

Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug;112(2):195-202. doi: 10.1016/j.tripleo.2011.02.037. Epub 2011 May 31.

PMID:
21622014
16.

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients.

Kastritis E, Roussou M, Michael M, Gavriatopoulou M, Michalis E, Migkou M, Delimpasi S, Kyrtsonis MC, Gogos D, Liapis K, Charitaki E, Repousis P, Terpos E, Dimopoulos MA; Greek Myeloma Study Group.

Br J Haematol. 2010 Sep;150(5):587-91. doi: 10.1111/j.1365-2141.2010.08288.x. Epub 2010 Jul 7.

PMID:
20618328
17.

Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.

Gkountouvas A, Kostoglou-Athanassiou I, Veniou E, Repousis P, Ziras N, Kaldrimidis P.

Thyroid. 2010 Jun;20(6):597-600. doi: 10.1089/thy.2010.0028.

PMID:
20553195
18.

High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.

Papanikolaou X, Maltezas D, Repousis P, Athanassopoulos A, Alexia S, Megalakaki K, Kotsopoulou M, Mitsouli-Mentzikof C.

J BUON. 2008 Apr-Jun;13(2):193-7.

PMID:
18555464
19.

Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.

Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C.

J BUON. 2007 Jan-Mar;12(1):41-4.

PMID:
17436400
20.

Candidemia in patients with acute leukemia.

Megalakaki C, Perlorentzou S, Dadakaridou M, Dima I, Repousis P, Mitsouli-Mentzikof C.

J BUON. 2006 Apr-Jun;11(2):191-5.

PMID:
17318970
21.

Prevalence of autoantibodies (ANA, anti ds-DNA, ENA, IMF) and rheumatic syndromes in patients with lymphoproliferative diseases.

Chloraki-Bobota A, Megalakaki C, Repousis P, Chalkiopoulou I, Lalaki I, Trafalis DT, Athanassiou AE, Mitsouli-Mentzikof C.

J BUON. 2006 Oct-Dec;11(4):485-9.

PMID:
17309182
22.

Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece.

Tzala S, Lord J, Ziras N, Repousis P, Potamianou A, Tzala E.

Eur J Health Econ. 2005 Jun;6(2):102-6.

PMID:
19787846
23.

Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.

Bogdanos J, Karamanolakis D, Milathianakis K, Repousis P, Chloraki-Bobota A, Majed H, Pagalou-Thoua E, Tsintavis A, Koutsilieris M.

Anticancer Res. 2004 May-Jun;24(3b):1957-61.

24.

Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.

Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, Tsintavis A, Koutsilieris M.

Anticancer Res. 2003 Mar-Apr;23(2C):1757-62.

PMID:
12820454
25.

A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.

Pangalis GA, Vassilakopoulos TP, Michalis E, Roussou P, Vrakidou E, Repousis P, Angelopoulou MK, Siakantaris MP, Korantzis J, Symeonidis A, Grigorakis V, Stefanoudakis E, Stamatellou M, Bourantas KL, Kalmantis T, Christopoulos G, Kokkinis G, Mihalakeas I, Papayiannis A; Hellenic Cooperative Lymphoma Group.

Leuk Lymphoma. 2003 Apr;44(4):635-44.

PMID:
12769340
26.

Chronic myelogenous leukemia terminating in acute megakaryoblastic leukemia. Case report.

Bourantas KL, Repousis P, Tsiara S, Christou L, Konstantinidou P, Bai M.

J Exp Clin Cancer Res. 1998 Jun;17(2):243-5.

PMID:
9700588
27.

Aplastic anemia. Report of a case with recurrent episodes in consecutive pregnancies.

Bourantas K, Makrydimas G, Georgiou I, Repousis P, Lolis D.

J Reprod Med. 1997 Oct;42(10):672-4.

PMID:
9350025
28.

Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis.

Bourantas KL, Tsiara S, Christou L, Repousis P, Konstantinidou P, Bai M, Seferiadis K.

Acta Haematol. 1996;96(2):79-82.

PMID:
8701705

Supplemental Content

Loading ...
Support Center